429677-00-9Relevant articles and documents
Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability
Giancola, JoLynn B.,Bonifazi, Alessandro,Cao, Jianjing,Ku, Therese,Haraczy, Alexandra J.,Lam, Jenny,Rais, Rana,Coggiano, Mark A.,Tanda, Gianluigi,Newman, Amy Hauck
, (2020/09/17)
Despite considerable efforts to develop medications to treat psychostimulant use disorders, none have proven effective, leaving an underserved patient population and unanswered questions as to what mechanism(s) of action should be targeted for developing
INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES
-
Paragraph 00546; 00547-00548, (2016/12/22)
Described herein are compounds of Formula (I'), Formula (IA), Formulae (I)-(VII), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrug sthereof. The invention also provides pharmaceutical compositions of the compounds for human and veterinary use. Compounds of the present invention are useful for inhibiting bacterial growth and therefore are useful in treating and/or preventing bacterial infections. Methods of using the compounds for treating and/or preventing a bacterial infection in a subject are also described.
QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
-
Paragraph 0578, (2015/09/28)
The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders
